The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...

1 In this article, we explore the impact of incretin-mimetic drugs on muscle health and what can be done to limit these severe side effects. Incretins are intestinal hormones secreted in response to ...

Research has shed light on the intricate mechanisms of insulin production in fruit flies, revealing surprising parallels with ...

In a phase 1b/2a trial subcutaneous amycretin demonstrated a safety profile similar to other incretin-based drugs . Adults ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...